Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions
| Autor: | Michelle T. Lee, Jerin George, Hunaina Shahab, Melody Hermel, Jamal S. Rana, Salim S. Virani |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Reviews and Scientific Meetings and New Research Implications (S. Virani
Section Editor) Aspirin Anticholesteremic Agents Empagliflozin COVID-19 Heart failure American Heart Association United States Cardiovascular prevention Cardiovascular Diseases Atherosclerotic cardiovascular disease Humans Proprotein Convertase 9 Cardiology and Cardiovascular Medicine Randomized Controlled Trials as Topic |
| Zdroj: | Current Atherosclerosis Reports |
| ISSN: | 1534-6242 1523-3804 |
| Popis: | Purpose of Review This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions. Recent Findings. Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Summary Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink